Cagrilintide Acetate 10mg

Cagrilintide — Long-Acting Amylin Analogue by Dragon Pharma

Cagrilintide is Dragon Pharma's formulation of the long-acting amylin analogue Cagrilintide at 10mg per vial — a novel once-weekly peptide developed by Novo Nordisk targeting amylin receptors (AMY1-3) for appetite suppression and body weight reduction through a mechanism entirely distinct from GLP-1 agonists. With an approximately 7-8 day half-life, a single vial covers multiple weekly doses.

Also searched as: Cagrilintide 10mg, amylin analogue peptide, CagriSema component, Cagrilintide Dragon Pharma.

What Is Amylin — And Why a Different Mechanism Matters

Amylin is a 37 amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. Unlike GLP-1 (which acts primarily on the hypothalamus and brainstem via the vagus nerve), amylin acts directly on the area postrema — a circumventricular organ in the brainstem that lacks a blood-brain barrier, making it uniquely accessible to circulating peptides:

• GLP-1 agonists (Tirzepatide, Semaglutide) primarily reduce appetite through hypothalamic signalling — slowing gastric emptying and reducing the reward value of food through central dopaminergic pathways
• Amylin analogues act on the area postrema and nucleus tractus solitarius — producing satiety signals through a neuronal circuit that is complementary and partially distinct from GLP-1's hypothalamic pathway
• This is why combining an amylin analogue with a GLP-1 agonist produces greater weight loss than either alone — they activate different satiety circuits simultaneously rather than redundantly stimulating the same pathway

Cagrilintide vs Native Amylin — What Makes It Long-Acting

Native amylin has a very short half-life (~10-15 minutes) — too short for practical therapeutic use. Cagrilintide addresses this through several structural modifications:

• Fatty acid conjugation enabling albumin binding (similar to the mechanism used in Semaglutide and CJC-1295 DAC) — extending the half-life from minutes to approximately 7-8 days
• Additional amino acid substitutions to resist enzymatic degradation
• The result is a once-weekly subcutaneous injection capable of maintaining sustained amylin receptor activation throughout the week
• Cagrilintide is structurally more stable than Pramlintide — the only previously approved amylin analogue (Symlin) which required 3× daily injection due to its short half-life

The CagriSema Clinical Data — The Most Significant Recent Development

Cagrilintide's most important clinical evidence comes from its combination with Semaglutide (GLP-1 agonist) in Novo Nordisk's CagriSema Phase III programme — data that most competitor content has not adequately covered:

The REDEFINE 1 data positions the CagriSema combination as a direct competitor to Tirzepatide — achieving approximately 22.7% body weight reduction at 68 weeks versus Tirzepatide's 20.9% at 72 weeks. This combination approach (amylin + GLP-1) represents the emerging frontier of peptide-based weight management beyond single-mechanism approaches.

Cagrilintide Standalone vs Combined with GLP-1 Agonists

Effects and Benefits

• Appetite suppression through area postrema amylin receptor activation — a pathway complementary to GLP-1's hypothalamic mechanism
• Slowed gastric emptying contributing to prolonged postprandial satiety
• Approximately 10-11% body weight reduction as monotherapy over 26 weeks (Phase II data)
• Synergistic weight loss when combined with GLP-1 agonists — additive mechanisms produce greater than either alone
• No suppression of natural testosterone — does not require Post Cycle Therapy
• Once-weekly dosing from the 7-8 day half-life

Dosage and Administration

At 10mg per vial and 2.4mg per weekly dose, one vial provides approximately 4 weeks of dosing at maintenance. Reconstitute with bacteriostatic water before use. Unlike peptides requiring fasted dosing, Cagrilintide's mechanism is not significantly affected by meal timing — once-weekly injection can be taken at any time.